In the last few weeks, three separate prospects reached out to us in what looked like sudden bursts of interest.

A question we hear often from biopharma leadership and investors: "With AI improving this fast, do we really need

There's a harmful posture across biopharma that is hampering meaningful progress: a belief that certain categories of work

Most onboarding journeys hit an early inflection point: a moment when it becomes clear whether the software will actually stick.

When your timelines are measured in years rather than weeks - as they are in the biopharma world - partnership

The right technical people can be a huge competitive advantage in industries like biopharma. The challenge becomes attracting and retaining

Two biotech companies, both developing promising therapeutics with strong scientific teams. In a board meeting, someone asks: "where do

We had a call this month with an SVP who's taken 11 compounds into clinic, across 6 biotechs.

In most biopharma organizations, the data story is the same. You have information scattered across every imaginable system: LIMS, ELNs,

Why is it so hard to get answers to pretty straightforward questions, when it comes to biotech data? And what